Current Neurology and Neuroscience Reports

, Volume 2, Issue 2, pp 134–141

New antiepileptic drugs: Comparative studies of efficacy and cognition

  • Steven L. Weinstein
  • Joan Conry


Over the past 10 years, the Food and Drug Administration has approved eight prophylactic antiepileptic drugs (AEDs). Although the goal of universal seizure control without side effects has not been reached, the tolerability of medications has improved. This paper reviews the AEDs introduced since 1993 and tries to objectively present comparative data obtained in double-blind studies.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE: Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998, 338:429–434.PubMedCrossRefGoogle Scholar
  2. 2.
    Arunkumar G, Wyllie E, Kotagal P, Ong HT, Gilliam F: Parent- and patient validated content for pediatric quality-of-life. Epilepsia 2000, 41:1474–1484. This was a study to validate a parent and child questionnaire regarding the quality of life in children with epilepsy. A limited number of domains were deemed important. More importantly, the tool provides insight into family, and not physician, concerns.PubMedCrossRefGoogle Scholar
  3. 3.
    Report of the ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998, 39:799–803.CrossRefGoogle Scholar
  4. 4.
    Marson AG, Chadwick DW: New drug treatments for epilepsy. J Neurol Neurosurg Psychiatry 2001, 70:143–155.PubMedCrossRefGoogle Scholar
  5. 5.
    Walker MC, Sander JW: Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology 1997, 49:333–337.PubMedGoogle Scholar
  6. 6.
    Sachdeo R: Challenging our past paradigm in the management of epilepsy. Neurology 2000; 55(suppl. 3):S1-S4.PubMedGoogle Scholar
  7. 7.
    Pellock JM: Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 1999, 104:1106–1116.PubMedCrossRefGoogle Scholar
  8. 8.
    Bourgeois BF: New antiepileptic drugs in children: which ones for which seizures? Clin Neuropharmacol 2000, 23:119–132. A detailed review of the new antiepiletpic medications. It provides the details of issues not covered in this paper, including the studies leading to approval, reported side effects, and pharmacology, including dosing suggestions. The author provides his opinion of what drugs should be utilized and when.PubMedCrossRefGoogle Scholar
  9. 9.
    Glauser TA: Expanding first-line therapy options for children with partial seizures. Neurology 2000, 55(suppl. 3):S30-S37.PubMedGoogle Scholar
  10. 10.
    Nieto-Barrera M, Brozmanova M, Capovilla G, et al., on behalf of the Lamicatal vs Carbamazepine Study Group: A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001, 46:145–155.PubMedCrossRefGoogle Scholar
  11. 11.
    Karceski S, Morrell M, Carpenter D: The expert consensus guideline series. Treatment of epilepsy. Epilepsy Behav 2001, 2:A1-A50. This is an interesting study if one wants to know what one’s colleagues are doing. A large number of scenarios have been sent to the experts as to what antiepileptic drug they would utilize. The responses are tallied and provided in an easy to read form. Good approach and science, but based on opinion.CrossRefGoogle Scholar
  12. 12.
    Mattson RH, Cramer JA, Collins JF, et al.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985, 313:145–151.PubMedCrossRefGoogle Scholar
  13. 13.
    Mattson RH, Cramer JA, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonicclonic seizures in adults. N Engl J Med 1992, 327:765–771.PubMedCrossRefGoogle Scholar
  14. 14.
    Rochat P, Hallas J, Gaist D, Friis ML: Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 2001, 104:6–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Lindberger M, Alenius M, Frisén L, et al., on behalf of the GREAT Study Investigators Group: Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. Epilepsia 2000, 41:1289–1295.PubMedGoogle Scholar
  16. 16.
    Steiner TJ, Dellaportas CI, Findley LJ, et al.: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999, 40:601–607.PubMedGoogle Scholar
  17. 17.
    Brodie MJ, Richens A, Yuen AW: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995, 345:476–479.PubMedCrossRefGoogle Scholar
  18. 18.
    Brodie MJ, Overstall PW, Giorgi L, for the UK Elderly Study Group: Lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999, 37:81–87.PubMedCrossRefGoogle Scholar
  19. 19.
    Reunanen M, Dam M, Yuen AW: A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996, 23:149–155.PubMedCrossRefGoogle Scholar
  20. 20.
    Guerreiro MM, Vigonius U, Pohlmann H, et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997, 27:205–213.PubMedCrossRefGoogle Scholar
  21. 21.
    Bill PA, Vigonius U, Pohlmann H, et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997, 27:195–204.PubMedCrossRefGoogle Scholar
  22. 22.
    Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ: Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987, 1:284–289.PubMedCrossRefGoogle Scholar
  23. 23.
    Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989, 3:70–76.PubMedCrossRefGoogle Scholar
  24. 24.
    Christe W, Kramer G, Vigonius U, et al.: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997, 26:451–460.PubMedCrossRefGoogle Scholar
  25. 25.
    Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med 2000, 342:314–319. The paper has important observations, including that the new drugs may not be adding much to our ability to make patients seizure free. Clearly, this approach will need to be constantly updated as even newer drugs are increasingly used. Also important is the finding that persons not responding to the first antiepileptic drugs probably have something quite wrong with their brain, and the chances of becoming seizure-free with any drug are small. Indirectly supports the argument for early surgical intervention.PubMedCrossRefGoogle Scholar
  26. 26.
    Lhatoo SD, Wong IC, Polizzi G, Sander JW: Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000, 41:1592–1596.PubMedCrossRefGoogle Scholar
  27. 27.
    Meador KJ, Gilliam FG, Kanner AM, Pellock JM: Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 2001, 2:SS1-SS17.PubMedCrossRefGoogle Scholar
  28. 28.
    Baker GA, Hesdon B, Marson AG: Quality-of-life and behavioral measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 2000, 41:1357–1363. A study performed about studies. Randomized controlled trials of antiepileptic drugs were reviewed to evaluate the methodologies used for assessing mood and quality of life. Concerns are expressed regarding the validity of the measures in the epilepsy population and failure to review previously defined methods (52 different exams were used in 46 trials).PubMedCrossRefGoogle Scholar
  29. 29.
    Leach JP, Girvan J, Paul A, Brodie MJ: Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psych 1997, 62:372–376.CrossRefGoogle Scholar
  30. 30.
    Mortimore C, Trimble M, Emmers E: Effects of gabapentin on cognition and quality of life in patients with epilepsy. Seizure 1998, 7:359–364.PubMedCrossRefGoogle Scholar
  31. 31.
    Meador KJ, Loring DW, Ray PG, et al.: Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999, 40:1279–1285.PubMedCrossRefGoogle Scholar
  32. 32.
    Martin R, Meador K, Turrentine L, et al.: Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 2001, 42:764–771.PubMedCrossRefGoogle Scholar
  33. 33.
    Smith D, Baker G, Dewey M, Chadwick DW: Outcomes of addon treatment with lamotrigine in partial epilepsy. Epilepsia 1993, 34:312–322.PubMedCrossRefGoogle Scholar
  34. 34.
    Meador KJ, Loring DW, Ray PG, et al.: Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001, 56:1177–1182. The study is not unique in its use of normal paid volunteers to assess the effects of a medication. The methodology of which tools are used in assessing the impact of the antiepilpetic drugs, however, rivals the best of any study. Many of the tasks have previously been demonstrated to be sensitive to these effects and a detailed description is provided.PubMedGoogle Scholar
  35. 35.
    Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW: Lamotrigine therapy for autistic disorder: a randomized, doubleblind, placebo-controlled trial. J Autism Dev Disord 2001, 31:175–181. Not an important study regarding the impact of lamotrignine therapy on autism. However, the observation that parents report significant improvement in spite of objective studies not demonstrating changes raises questions regarding reports of medication side effects in drug trials, or perhaps the ability of standardized tests to demonstrate what they purport to do.PubMedCrossRefGoogle Scholar
  36. 36.
    Cramer JA, Arrigo C, Van Hammee G, Gauer LJ, Cereghino JJ, for the N132 Study Group: Effect of levetiracetam on epilepsyrelated quality of life. Epilepsia 2000, 41:868–874. This study assesses the effects of levetiracetam upon the quality of life in patients with partial seizures. The importance of the paper is the clear impact of decreasing seizures in a trial and how it can influence apparent objective measures of overall functioning, not specifically from drug effects on the brain.PubMedCrossRefGoogle Scholar
  37. 37.
    Neyens LG, Alpherts WC, Aldenkamp AP: Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuro-Psychopharmacol Biol Psychiatry 1995, 19:411–419.CrossRefGoogle Scholar
  38. 38.
    Curran HV, Java R: Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993, 44:529–533.PubMedCrossRefGoogle Scholar
  39. 39.
    Aikia M, Kalviainen R, Sivenius J, Halonen T, Riekkinen PJ: Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992, 11:199–203.PubMedCrossRefGoogle Scholar
  40. 40.
    Dodrill CB, Arnett JL, Sommerville KW, Shu V: Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997, 48:1025–1031.PubMedGoogle Scholar
  41. 41.
    Dodrill CB, Arnett JL, Shu V, et al.: Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998, 39:33–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Dodrill CB, Arnett JL, Deaton R, Lenz GT, Sommerville KW: Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res 2000, 42:123–132.PubMedCrossRefGoogle Scholar
  43. 43.
    Cramer J, Ryan J, Chang J, Sommerville K, and M92-825 Study Group: The short-term impact of adjunctive tiagabine on health-related quality of life. Epilepsia 2001, 42(suppl. 3):70–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Aldenkamp AP, Baker G, Mulder OG, et al.: A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000, 41:1167–1178.PubMedCrossRefGoogle Scholar
  45. 45.
    Berent S, Sackellares JC, Giordani B, et al.: Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987, 28:61–67.PubMedGoogle Scholar
  46. 46.
    Akaho R: The effects of antiepileptic drugs on cognition in normal volunteers. Psychol Clin Neurosci 1996, 50:61–69.CrossRefGoogle Scholar
  47. 47.
    Martin R, Kuzniecky R, Ho S, et al.: Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999, 52:321–327.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Steven L. Weinstein
    • 1
  • Joan Conry
    • 1
  1. 1.Department of NeurologyChildren’s National Health CenterWashingtonUSA

Personalised recommendations